US Patent

US11219662 — Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II

Method of Use · Assigned to La Jolla Pharma LLC · Expires 2037-01-06 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating hypotension in a patient who has received an ACE inhibitor by administering angiotensin II.

USPTO Abstract

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3262 — angiotensin-ii-acetate
U-3262 — angiotensin-ii-acetate
U-3262 — angiotensin-ii-acetate

Patent Metadata

Patent number
US11219662
Jurisdiction
US
Classification
Method of Use
Expires
2037-01-06
Drug substance claim
No
Drug product claim
No
Assignee
La Jolla Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.